Results 21 to 30 of about 4,852 (207)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. [PDF]

PLoS ONE, 2019
BackgroundBecause tenofovir alafenamide (TAF) leads to significantly lower plasma tenofovir concentrations than tenofovir disoproxil fumarate (TDF) and is a stronger substrate for P-glycoprotein (P-gp) than TDF, TAF could lead to decreased central ...
Linn Hermansson, Aylin Yilmaz, Richard W Price, Staffan Nilsson, Scott McCallister, Tariro Makadzange, Moupali Das, Henrik Zetterberg, Kaj Blennow, Magnus Gisslen   +9 more
doaj   +6 more sources

Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece

Journal of Comparative Effectiveness Research
Aim: This study assessed the clinical impact and cost–effectiveness of switching from tenofovir disoproxil fumarate (TDF) to either tenofovir alafenamide (TAF) or entecavir (ETV) in a Greek chronic hepatitis B (CHB) population.
Emmanouil Sinakos, Nandita Kachru, Christos Tsoulas, Sushanth Jeyakumar, Nathaniel J Smith, Alon Yehoshua, Evangelos Cholongitas   +6 more
doaj   +2 more sources

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum. [PDF]

Clin Infect Dis
Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S, IMPAACT 2010/VESTED Study Team.   +28 more
europepmc   +3 more sources

Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection [PDF]

The Journal of Infectious Diseases, 2017
Tenofovir alafenamide fumarate (TAF), a new prodrug of tenofovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved in the United States and Europe for treating adolescents and adults with chronic hepatitis B infection. TAF is formulated to deliver the active metabolite to target cells more efficiently than TDF at lower
Marı́a Buti, Mar Riveiro‐Barciela, Rafael Esteban   +2 more
openalex   +3 more sources

Tenofovir alafenamide fumarate

Antiviral Therapy, 2022
Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV.
William A Lee, Andrew K Cheng
openaire   +2 more sources

Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma. [PDF]

Antimicrob Agents Chemother, 2020
Tenofovir (TFV) alafenamide fumarate (TAF) is an antiretroviral that has been evaluated in alternative drug delivery systems in several species. The ex vivo stability of TAF was evaluated, and TAF was stable in dog-, sheep-, and macaque-spiked plasma.
Parsons TL, Gwenden KN, Marzinke MA.
europepmc   +4 more sources

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Lancet, The, 2020
Kenneth Mayer, Peter L Anderson, Robert M Grant   +2 more
exaly   +3 more sources

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial [PDF]

J Viral Hepat
ABSTRACT The optimal strategy for chronic hepatitis B virus (HBV) infected patients with negative hepatitis B e‐antigen (HBeAg) and normal alanine aminotransferase (ALT) remains uncertain. This study aimed to evaluate the safety and efficacy of tenofovir alafenamide fumarate (TAF) treatment in this patient population.
Luo Q, Xu W, Zhang Y, Li X, Lai J, Li J, Zheng X, Deng H, Chen L, Zhu X, Xie C, Peng L.   +11 more
europepmc   +2 more sources

Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday

Molecules, 2021
Nucleoside and nucleotide analogues are essential antivirals in the treatment of infectious diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV), varicella-zoster virus (VZV ...
Guangdi Li, Tingting Yue, Pan Zhang, Weijie Gu, Ling-Jie Gao, Li Tan   +5 more
doaj   +1 more source

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV

Journal of Virus Eradication, 2021
This article evaluates the evidence supporting use of the tenofovir disoproxil fumarate (TDF) plus lamivudine (3​TC) combination as a dual nucleoside backbone within a triple drug antiretroviral regimen.
Laura Waters, Viraj Mehta, Jaideep Gogtay, Marta Boffito   +3 more
doaj   +1 more source